Search

Author/Creator Risitano, A.

5. P825: FACTOR D INHIBITION WITH ORAL BCX9930 MONOTHERAPY LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA NAÏVE TO C5 INHIBITORS. (23rd June 2022)

Authors:
McDonald, A.; Malherbe, J. L. R.; Kulasekararaj, A.; Füreder, W.; Griffin, M.; Cornpropst, M.; Farmer, M. K.; Kargl, D.; Collins, D.; Sheridan, W.; Risitano, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
719
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. P826: FACTOR D INHIBITION WITH ORAL BCX9930 LEADS TO SUSTAINED CONTROL OF HEMOLYSIS AND SYMPTOMS OVER 48 WEEKS IN SUBJECTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS. (23rd June 2022)

Authors:
Kulasekararaj, A.; Füreder, W.; McDonald, A.; Malherbe, J. L. R.; Gandhi, S.; Collins, D.; Cornpropst, M.; Dobo, S.; Farmer, M. K.; Kargl, D.; Sheridan, W.; Griffin, M.; Risitano, A.
Journal:
HemaSphere
Issue:
Volume 6(2022)Supplement 3
Page Start:
720
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗